Essential medicines for breast cancer in low and middle income countries.
about
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.Essential medicines for cancer: WHO recommendations and national priorities.Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.The evolution of biosimilars in oncology, with a focus on trastuzumab.
P2860
Essential medicines for breast cancer in low and middle income countries.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Essential medicines for breast cancer in low and middle income countries.
@ast
Essential medicines for breast cancer in low and middle income countries.
@en
type
label
Essential medicines for breast cancer in low and middle income countries.
@ast
Essential medicines for breast cancer in low and middle income countries.
@en
prefLabel
Essential medicines for breast cancer in low and middle income countries.
@ast
Essential medicines for breast cancer in low and middle income countries.
@en
P2093
P2860
P1433
P1476
Essential medicines for breast cancer in low and middle income countries.
@en
P2093
Aukje K Mantel-Teeuwisse
H G M Leufkens
J H M Schellens
Y T Bazargani
P2860
P2888
P356
10.1186/S12885-015-1583-4
P407
P577
2015-08-18T00:00:00Z
P5875
P6179
1011361228